Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
About this item
Full title
Author / Creator
Bapineuzumab 301 and 302 Clinical Trial Investigators , Salloway, Stephen , Sperling, Reisa , Fox, Nick C , Blennow, Kaj , Klunk, William , Raskind, Murray , Sabbagh, Marwan , Honig, Lawrence S , Porsteinsson, Anton P , Ferris, Steven , Reichert, Marcel , Ketter, Nzeera , Nejadnik, Bijan , Guenzler, Volkmar , Miloslavsky, Maja , Wang, Daniel , Lu, Yuan , Lull, Julia , Tudor, Iulia Cristina , Liu, Enchi , Grundman, Michael , Yuen, Eric , Black, Ronald and Brashear, H. Robert
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In two phase 3 trials in patients with Alzheimer's disease, bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, did not improve clinical outcomes. Amyloid-related edema was more likely to develop in patients treated with bapineuzumab.
Alzheimer's disease, a neurodegenerative disease resulting in progressive dementia, is characterize...
Alternative Titles
Full title
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Authors, Artists and Contributors
Author / Creator
Salloway, Stephen
Sperling, Reisa
Fox, Nick C
Blennow, Kaj
Klunk, William
Raskind, Murray
Sabbagh, Marwan
Honig, Lawrence S
Porsteinsson, Anton P
Ferris, Steven
Reichert, Marcel
Ketter, Nzeera
Nejadnik, Bijan
Guenzler, Volkmar
Miloslavsky, Maja
Wang, Daniel
Lu, Yuan
Lull, Julia
Tudor, Iulia Cristina
Liu, Enchi
Grundman, Michael
Yuen, Eric
Black, Ronald
Brashear, H. Robert
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_gup_ub_gu_se_196039
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_196039
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1304839
